-
1.发明公开公开(公告)号：US20240066123A1
公开(公告)日：2024-02-29
申请号：US18336889
申请日：2023-06-16
Applicant: Bristol-Myers Squibb Company
Inventor： Lori S. BURTON , William Ying , Nils Lonberg , Sudhir Chakravarthi , Pedro Smith
IPC: A61K39/395 , A61K9/00 , A61K45/06 , A61K47/02 , A61K47/12 , A61K47/18 , A61K47/22 , A61K47/26 , A61K47/34 , C07K16/28
CPC classification number: A61K39/39591 , A61K9/0019 , A61K39/3955 , A61K45/06 , A61K47/02 , A61K47/12 , A61K47/183 , A61K47/22 , A61K47/26 , A61K47/34 , C07K16/2803 , C07K16/2818 , C07K16/2827 , A61J1/1412
Abstract: This provides pharmaceutical compositions that comprise (i) an anti-LAG-3 antibody or antigen binding fragment thereof or (ii) an anti-LAG-3 antibody or antigen binding fragment thereof and an anti-PD-1 antibody, anti-PD-L1 antibody, or antigen binding fragment thereof. Also provided are pharmaceutical compositions that comprise a buffering agent, stabilizing or bulking agent, and a surfactant. The disclosure also provides a vial, syringe, intravenous bag, or kit that comprises the compositions, and methods for using the compositions.
-
公开(公告)号：US11807686B2
公开(公告)日：2023-11-07
申请号：US16616574
申请日：2018-05-30
Applicant: Bristol-Myers Squibb Company
Inventor： James Novotny, Jr. , Nils Lonberg , Cyrus Hedvat , Raphael Clynes , Darren Locke , John P. Cogswell , Jeffrey Jackson , Christopher Harbison , Robin Edwards
IPC: C07K16/28 , A61P35/00 , A61K39/00 , G01N33/574
CPC classification number: C07K16/2827 , A61P35/00 , C07K16/2818 , G01N33/574 , A61K2039/507
Abstract: The invention provides a method of treating a tumor in a human patient comprising (i) identifying a patient as having a LAG-3 positive tumor and (ii) administering to the patient a PD-1 pathway inhibitor, a combination of a PD1 pathway inhibitor and an immune checkpoint inhibitor, a combination of a LAG-3 inhibitor and a PD-1 pathway inhibitor, or an anti-CTLA4 antibody. In some embodiments, the method further comprises identifying the patient as having a LAG-3 positive PD-L1 positive tumor. In some embodiments, the LAG-3 inhibitor is an anti-LAG-3 antibody and the PD-1 pathway inhibitor is an anti-PD-1 antibody. The methods of the invention can improve response rates to treatment with a PD-1 pathway inhibitor, a combination of a PD1 pathway inhibitor and an immune checkpoint inhibitor, or a combination of a LAG-3 inhibitor and a PD-1 pathway inhibitor.
-
3.发明授权公开(公告)号：US11084881B2
公开(公告)日：2021-08-10
申请号：US16578987
申请日：2019-09-23
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Changyu Wang , Nils Lonberg , Alan J. Korman , Mark J. Selby , Mohan Srinivasan , Karla Henning , Michelle Minhua Han , Guodong Chen , Richard Huang , Indrani Chakraborty , Haichun Huang , Susan Wong , Huiming Li
IPC: C12N15/13 , C07K16/28 , A61K39/395 , G01N33/68 , G01N33/574 , A61K39/00 , A61K47/68
Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.
-
4.发明授权公开(公告)号：US10465010B2
公开(公告)日：2019-11-05
申请号：US15646558
申请日：2017-07-11
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Changyu Wang , Nils Lonberg , Alan J. Korman , Mark J. Selby , Mohan Srinivasan , Karla Henning , Michelle Minhua Han , Guodong Chen , Richard Huang , Indrani Chakraborty , Haichun Huang , Susan Wong , Huiming Li
IPC: C07K16/00 , C07H21/00 , C07K16/28 , A61K39/395 , G01N33/68 , G01N33/574 , A61K39/00 , A61K47/68
Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.
-
5.发明授权公开(公告)号：US10266591B2
公开(公告)日：2019-04-23
申请号：US15296290
申请日：2016-10-18
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Nils Lonberg , Mohan Srinivasan
Abstract: The present invention provides isolated monoclonal antibodies that specifically bind LAG-3, and have optimized functional properties compared to previously described anti-LAG-3 antibodies, such as antibody 25F7 (US 2011/0150892 A1). These properties include reduced deamidation sites, while still retaining high affinity binding to human LAG-3, and physical (i.e., thermal and chemical) stability. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided, as well as immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies. The present invention also provides methods for detecting LAG-3, as well as methods for treating stimulating immune responses using an anti-LAG-3 antibody of the invention. Combination therapy, in which the antibodies are co-administered with at least one additional immunostimulatory antibody, is also provided.
-
Patent Agency Ranking
公开(公告)号：US10100129B2
公开(公告)日：2018-10-16
申请号：US15520638
申请日：2015-11-19
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Nils Lonberg , Alan J. Korman , Bryan C. Barnhart , Aaron P. Yamniuk , Mohan Srinivasan , Karla A. Henning , Ming Lei , Emanuela Sega , Angela Goodenough , Maria Jure-Kunkel , Guodong Chen , John S. Sack , Richard Y. Huang , Martin J. Corbett , Joseph E. Myers, Jr. , Liang Schweizer , Sandra V. Hatcher , Haichun Huang , Pingping Zhang
IPC: A61K39/00 , C07K16/40 , C07K16/28 , A61K47/68 , C07K16/30 , A61K39/395 , A61K45/06 , G01N33/574
Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the disclosure are also provided. The disclosure also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the disclosure, including methods for treating various cancers.
-
公开(公告)号：US20160145350A1
公开(公告)日：2016-05-26
申请号：US14994828
申请日：2016-01-13
Applicant: Bristol-Myers Squibb Company
Inventor： Nils Lonberg , Alan J. Korman , Bryan C. Barnhart , Aaron P. Yamniuk , Mohan Srinivasan , Karla A. Henning , Ming Lei , Emanuela Sega , Angela Goodenough , Maria N. Jure-Kunkel , Guodong Chen , John S. Sack , Richard Huang , Martin J. Corbett , Joseph E. Myers, JR. , Liang Schweizer , Sandra V. Hatcher
IPC: C07K16/40 , G01N33/573 , A61K39/395 , A61K47/48 , C07K16/30 , A61K45/06
CPC classification number: C07K16/40 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/2896 , C07K16/30 , C07K16/3015 , C07K16/3023 , C07K16/303 , C07K16/3038 , C07K16/3046 , C07K16/3053 , C07K16/3061 , C07K16/3069 , C07K2317/21 , C07K2317/31 , C07K2317/34 , C07K2317/52 , C07K2317/522 , C07K2317/524 , C07K2317/526 , C07K2317/53 , C07K2317/54 , C07K2317/55 , C07K2317/565 , C07K2317/567 , C07K2317/71 , C07K2317/72 , C07K2317/76 , C07K2317/77 , C07K2317/92 , C07K2317/94 , G01N33/573 , G01N2333/916
Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.
Abstract translation: 本发明提供分离的单克隆抗体，特别是人抗体，其以高亲和力结合人类分化簇73（CD73），并且抑制CD73的活性，并任选介导抗体依赖性CD73内化。 还提供了编码本发明抗体的核酸分子，表达载体，宿主细胞和用于表达本发明的抗体的方法。 还提供了免疫偶联物，双特异性分子和包含本发明抗体的药物组合物。 本发明还提供了使用本发明的抗体抑制表达CD73的肿瘤细胞生长的方法，包括治疗各种癌症的方法。
-
公开(公告)号：US11723975B2
公开(公告)日：2023-08-15
申请号：US16616583
申请日：2018-05-30
Applicant: Bristol-Myers Squibb Company
Inventor： Lori S. Burton , William Ying , Nils Lonberg , Sudhir Chakravarthi , Pedro Smith
IPC: A61K39/395 , A61K9/00 , A61K45/06 , A61K47/02 , A61K47/12 , A61K47/18 , A61K47/22 , A61K47/26 , A61K47/34 , C07K16/28 , A61J1/14 , A61K39/00
CPC classification number: A61K39/39591 , A61K9/0019 , A61K39/3955 , A61K45/06 , A61K47/02 , A61K47/12 , A61K47/183 , A61K47/22 , A61K47/26 , A61K47/34 , C07K16/2803 , C07K16/2818 , C07K16/2827 , A61J1/1412 , A61K2039/54 , A61K2039/545 , C07K2317/21 , C07K2317/24 , C07K2317/565
Abstract: This provides pharmaceutical compositions that comprise (i) an anti-LAG-3 antibody or antigen binding fragment thereof or (ii) an anti-LAG-3 antibody or antigen binding fragment thereof and an anti-PD-1 antibody, anti-PD-L1 antibody, or antigen binding fragment thereof. Also provided are pharmaceutical compositions that comprise a buffering agent, stabilizing or bulking agent, and a surfactant. The disclosure also provides a vial, syringe, intravenous bag, or kit that comprises the compositions, and methods for using the compositions.
-
公开(公告)号：US11213586B2
公开(公告)日：2022-01-04
申请号：US15776591
申请日：2016-11-17
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Changyu Wang , Nils Lonberg , Alan J. Korman , Mark J. Selby , Mohan Srinivasan , Karla A. Henning , Michelle Minhua Han , Guodong Chen , Richard Y. Huang , Indrani Chakraborty , Haichun Huang , Susan Chien-Szu Wong , Huiming Li , Bryan C. Barnhart , Aaron P. Yamniuk , Ming Lei , Liang Schweizer , Sandra V. Hatcher , Arvind Rajpal
IPC: C07K16/28 , A61K39/395 , G01N33/574 , G01N33/68 , A61K39/00
Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.
-
10.发明授权公开(公告)号：US10377824B2
公开(公告)日：2019-08-13
申请号：US16125028
申请日：2018-09-07
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Nils Lonberg , Mohan Srinivasan
Abstract: The present invention provides isolated monoclonal antibodies that specifically bind LAG-3, and have optimized functional properties compared to previously described anti-LAG-3 antibodies, such as antibody 25F7 (US 2011/0150892 A1). These properties include reduced deamidation sites, while still retaining high affinity binding to human LAG-3, and physical (i.e., thermal and chemical) stability. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided, as well as immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies. The present invention also provides methods for detecting LAG-3, as well as methods for treating stimulating immune responses using an anti-LAG-3 antibody of the invention. Combination therapy, in which the antibodies are co-administered with at least one additional immunostimulatory antibody, is also provided.
-
-
-
-
-
-
-
-
-
Search Results
29
records
(took 0.047 seconds)
